TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early stages.

AAIC 2025 Lecanemab Preserves Memory Over 4 Years in Early AD Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a ...

AAIC 2025 Lecanemab Preserves Memory Over 4 Years in Early AD Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a ...